A Study of MM-121 Combination Therapy in Patients With Advanced Non-Small Cell Lung Cancer
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Victor Moyo, MD
Merrimack Pharmaceuticals
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
38 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Facility name not stated
Edmonton, Alberta, Canada
- Facility name not stated
Toronto, Ontario, Canada
- Facility name not stated
Montreal, Quebec, Canada
- Facility name not stated
Heidelberg, Mannheim, Germany
- Facility name not stated
Bad Berka, Germany
- Facility name not stated
Frankfurt, Germany
- Facility name not stated
Heidelberg, Germany
- Facility name not stated
Lungenklinik, Germany
- Facility name not stated
Ulm, Germany
- Facility name not stated
Seoul, Gangnam-gu, South Korea
- Facility name not stated
Seoul, Seodaemun-gu, South Korea
- Facility name not stated
Barcelona, Spain
- Facility name not stated
Madrid, Spain
- Facility name not stated
Málaga, Spain
- Facility name not stated
Guishan, Taoyuan County, Taiwan
- Facility name not stated
Taichung, Taiwan
- Facility name not stated
Taichung, Taiwan
- Facility name not stated
Tainan, Taiwan
- Facility name not stated
Taipei, Taiwan
- Facility name not stated
Birmingham, Alabama, United States
- Facility name not stated
Tucson, Arizona, United States
- Facility name not stated
Loma Linda, California, United States
- Facility name not stated
Sacramento, California, United States
- Facility name not stated
San Francisco, California, United States
- Facility name not stated
Aurora, Colorado, United States
- Facility name not stated
Tampa, Florida, United States
- Facility name not stated
Atlanta, Georgia, United States
- Facility name not stated
Lafayette, Indiana, United States
- Facility name not stated
Boston, Massachusetts, United States
- Facility name not stated
St Louis, Missouri, United States
- Facility name not stated
Buffalo, New York, United States
- Facility name not stated
New York, New York, United States
- Facility name not stated
Cincinnati, Ohio, United States
- Facility name not stated
Portland, Oregon, United States
- Facility name not stated
Pittsburgh, Pennsylvania, United States
- Facility name not stated
Charleston, South Carolina, United States
- Facility name not stated
Nashville, Tennessee, United States
- Facility name not stated
Dallas, Texas, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 28 Feb 2010
- Primary completion
- 30 Nov 2014
- Completion
- 30 Jun 2015
- Last update posted
- 22 Aug 2016
- Registered enrollment
- 162
- Registry id
- NCT00994123
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.